Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
Article Date
October 13, 2023
This article is featured on another website.
Go to article
No items found.